View
5.618
Download
2
Tags:
Embed Size (px)
DESCRIPTION
HIV testing methodologies: an Introduction for more presentations and tutorials visit http://www.ubio.in
Citation preview
© 2008 ubio. All rights reserved. 2
diagnosis of infectionacute, recent, established or late stage disease
prognostic markersmonitoring of ARV therapies
immunological and virological markerstoxicities
diagnosis of opportunistic infectionsdrug resistance testing
Laboratory Tests
© 2008 ubio. All rights reserved. 3
Typical Primary HIV-1 Infection
symptoms
HIV-1 p24 antigen
0 1 2 3 4 5 6 / 2 4 6 8 10weeks years
HIV antibodies
Time following infection
HIV viral load
HIV proviral DNA
symptoms
‘window’period
1° infection
© 2008 ubio. All rights reserved. 4
Types of HIV Assays
DIAGNOSIS
Virus Detection & Quantification
Antibody
Antigen
Detection
RNAmodified Ag
Viral Culture, phenotyping
CD4+
ARV Resistance – genotypingARV Sensitivity
EIASimple, rapid tests Immunoblots
Incident assays
MANAGEMENT
DNA(RNA)
© 2008 ubio. All rights reserved. 5
HIV Test Spectrum
DNA PCRDNA PCRRNA PCRRNA PCR
p24 Agp24 Ag3rd gen ELISA1st gen ELISA
Detuned ELISA1wk 2wk 3wk 2mo 6mo 1yr 2yr 3yr +8yr
gp160gp120
p68p55p53
gp41-45
p40
p34
p24
p18
p12
gp160gp120
p68p55p53
gp41-45
p40
p34
p24
p18
p12
gp160gp120
p68p55p53
gp41-45
p40
p34
p24
p18
p12
early recent / established advanced
© 2008 ubio. All rights reserved. 6
HIV p24 antigen– serologyIn isolation or Ab/Ag Combo test Diagnosis of primary infection viraemia
Virus culture/isolation Nucleic acid detection (NAT)
Clinical uses Proviral DNA vs. plasma RNA(viral load) resolution of
inconclusive serology/neonatalsubtypingdrug resistance monitoring
Direct Virus Detection
© 2008 ubio. All rights reserved. 7
Principle of Immunoassays
SOLID PHASESOLID PHASESOLID PHASESOLID PHASE
ANTIGEN
SAMPLE ANTIBODY
ANTI-HUMAN IMMUNOGLOBULIN WITH DETECTOR
© 2008 ubio. All rights reserved. 8
EIAs including rapid, simple assaysparticle agglutinationdot/blotWestern blotAntigen and Antibody/Antigen (Ab/Ag)Incidence assays
Direct Virus Detection
Available Assays
© 2008 ubio. All rights reserved. 9
Dot/Blot Assays
© 2008 ubio. All rights reserved. 10
Particle Agglutination Assays
© 2008 ubio. All rights reserved. 11
technically more difficult visual interpretation lack standardisation
Performance
Interpretation ‘Gold Standard’ for confirmation
Western Blot
© 2008 ubio. All rights reserved. 12
Difficulties in interpretation Limitations - ‘window period’ antibodies appear within 3-4 weeks
Direct detection for early detectionHIV p24 antigenDNA/RNA (NAT)
Combo test = earlier detection Primary infection + therapy = delayed antibody
response Incident populations – ‘at risk’
Antibody Testing: Limitations
© 2008 ubio. All rights reserved. 13
Detection of Ag & Ab in a single test
utility in primary infection – pre-seroconversion ‘window period’
Useful for blood banks Automated platforms available
Ag/Ab Combo Tests
Ag & AbAg & AbAg & AbAg & Ab
© 2008 ubio. All rights reserved. 14
Chance of false reactivityMight need confirmation testsReplacement by other assays
(especially in the USA)More expensive than Antibody assays
Ag/Ab Assays: Limitations
© 2008 ubio. All rights reserved. 15
Detect HIV-1 & HIV-2 Cannot differentiate between HIV types Procedural control using anti human IgG Can test using whole blood, serum or
plasma Widely available No additional reagents required Storage at room temperature 15 minutes to get result
Simple Assays: HIV Determine
© 2008 ubio. All rights reserved. 16
Detects HIV-1 and HIV-2Will differentiate between types 1 and 2Procedural control using anti-human IgGSerum/plasma only Need additional reagents (included in kit)Requires refrigerated storage ‘Immunoconcentration’ principle15 minutes to result
BioRad HIV-1/2 Multispot
© 2008 ubio. All rights reserved. 17
Strategy I: Test all samples with one EIA Strategy II: Strategy I with all reactives retested in a more
specific test with different principle and/or antigen. Strategy III: Strategy II with reactives tested in a third test
differing from the first two tests. Transfusion Safety
Strategy I Surveillance
>10% Strategy I, < 10% Strategy II Diagnosis
>10% Strategy II, < 10% Strategy III
WHO Test Strategies
© 2008 ubio. All rights reserved. 18
Use strategy for confirmationUse combination of affordable and simple assaysUse tests with different principlesUse different antigen preparations
Use two or three types of ELISAs or rapid tests diagnosis confirmed by second sample Use direct detection of virus (PCR) for final
confirmation Important: Always use a QC sample
WHO Test Guidelines
© 2008 ubio. All rights reserved. 19
www.ubio.in